Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mirror polydactyly-vertebral segmentation-limbs defects syndrome is characterized by mirror polydactyly, vertebral hypersegmentation and severe congenital limb deficiencies. Duodenal atresia and absent thymus were also reported. So far, it has been described in four unrelated infants identified through a congenital malformation screening program carried out in Spain. The prevalence was estimated at around 1 in 330,000. The etiology is unknown but it was suggested that the syndrome is caused by defective expression of a developmental control gene.
Biomarker and diagnostic research for mirror polydactyly-vertebral segmentation-limbs defects syndrome has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
No clinical trials have been registered for mirror polydactyly-vertebral segmentation-limbs defects syndrome.
74 publications have been identified in PubMed for mirror polydactyly-vertebral segmentation-limbs defects syndrome. Research spans Basic Science / Preclinical (48%), Case Report / Case Series (22%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 31 | 48% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 4:02 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies |
14 |
22% |
Research summaries | 12 | 18% |
Testing and diagnosis research | 3 | 5% |
Disease patterns and progression | 2 | 3% |
New treatment approaches | 2 | 3% |
Clinical study results | 1 | 2% |
Coppola MR (2026). [PMID: 41159851](https://pubmed.ncbi.nlm.nih.gov/41159851/). *FEBS J*. [Basic Science / Preclinical]
Kabir A (2026). [PMID: 41701387](https://pubmed.ncbi.nlm.nih.gov/41701387/). *J Clin Immunol*. [Epidemiology / Natural History]
Law MA (2026). [PMID: 28613756](https://pubmed.ncbi.nlm.nih.gov/28613756/). *Unknown Journal*. [Basic Science / Preclinical]
Yu D (2026). [PMID: 41836559](https://pubmed.ncbi.nlm.nih.gov/41836559/). *J Orthop Translat*. [Basic Science / Preclinical]
Peymani F (2026). [PMID: 40302207](https://pubmed.ncbi.nlm.nih.gov/40302207/). *Brain*. [Basic Science / Preclinical]
Liu CZ (2026). [PMID: 41648231](https://pubmed.ncbi.nlm.nih.gov/41648231/). *bioRxiv*. [Basic Science / Preclinical]
Yogeshwar SM (2026). [PMID: 40650880](https://pubmed.ncbi.nlm.nih.gov/40650880/). *Brain*. [Basic Science / Preclinical]
Kanji AM (2026). [PMID: 42027841](https://pubmed.ncbi.nlm.nih.gov/42027841/). *Radiol Case Rep*. [Case Report / Case Series]
Shi W (2026). [PMID: 41513171](https://pubmed.ncbi.nlm.nih.gov/41513171/). *Brain Res Bull*. [Basic Science / Preclinical]
Mendez R (2026). [PMID: 41808409](https://pubmed.ncbi.nlm.nih.gov/41808409/). *HGG Adv*. [Case Report / Case Series]